Literature DB >> 24535838

Cancer progression and substance P.

Rafael Coveñas1, Miguel Muñoz2.   

Abstract

The substance P (SP)/neurokinin (NK)-1 receptor system plays an important role in cancer. After binding to the NK-1 receptor, SP induces tumor cell proliferation, migration of tumor cells (invasion, infiltration and metastasis) and angiogenesis. In contrast, NK-1 receptor antagonists inhibit tumor cell proliferation (tumor cells die by apoptosis), block the migratory activity of tumor cells, and exert antiangiogenic properties. The induction of apoptosis offers an appropriate method for cancer treatment. The NK-1 receptor can be considered as a target in cancer treatment. A common mechanism for cancer cell proliferation mediated by SP and the NK-1 receptor occurs and NK-1 receptor antagonists are broad-spectrum antineoplastic drugs. The NK-1 receptor antagonist aprepitant is used in clinical practice and exerts an antitumor action against a large number of different human tumor cells. In the future, such antitumor action should be tested in human clinical trials.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24535838     DOI: 10.14670/HH-29.881

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  16 in total

1.  The role of substance P/neurokinin 1 receptor in the pathogenesis of esophageal squamous cell carcinoma through constitutively active PI3K/Akt/NF-κB signal transduction pathways.

Authors:  Hossein Javid; Jahanbakhsh Asadi; Farnaz Zahedi Avval; Amir R Afshari; Seyed Isaac Hashemy
Journal:  Mol Biol Rep       Date:  2020-02-18       Impact factor: 2.316

2.  Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in breast cancer.

Authors:  Monireh Davoodian; Nadia Boroumand; Mostafa Mehrabi Bahar; Amir Hosein Jafarian; Mahdi Asadi; Seyed Isaac Hashemy
Journal:  Mol Biol Rep       Date:  2019-01-25       Impact factor: 2.316

3.  Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.

Authors:  Richard E Kast; Susana Ramiro; Sandra Lladó; Salvador Toro; Rafael Coveñas; Miguel Muñoz
Journal:  J Neurooncol       Date:  2015-11-24       Impact factor: 4.130

Review 4.  Neurotransmitters: emerging targets in cancer.

Authors:  Shu-Heng Jiang; Li-Peng Hu; Xu Wang; Jun Li; Zhi-Gang Zhang
Journal:  Oncogene       Date:  2019-09-16       Impact factor: 9.867

5.  Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis.

Authors:  James Yarmolinsky; Virginia Díez-Obrero; Tom G Richardson; Marie Pigeyre; Jennifer Sjaarda; Guillaume Paré; Venexia M Walker; Emma E Vincent; Vanessa Y Tan; Mireia Obón-Santacana; Demetrius Albanes; Jochen Hampe; Andrea Gsur; Heather Hampel; Rish K Pai; Mark Jenkins; Steven Gallinger; Graham Casey; Wei Zheng; Christopher I Amos; George Davey Smith; Richard M Martin; Victor Moreno
Journal:  PLoS Med       Date:  2022-02-03       Impact factor: 11.069

Review 6.  Targeting NK-1 Receptors to Prevent and Treat Pancreatic Cancer: a New Therapeutic Approach.

Authors:  Miguel Muñoz; Rafael Coveñas
Journal:  Cancers (Basel)       Date:  2015-07-06       Impact factor: 6.639

7.  Using Gelatin Nanoparticle Mediated Intranasal Delivery of Neuropeptide Substance P to Enhance Neuro-Recovery in Hemiparkinsonian Rats.

Authors:  Ying-Zheng Zhao; Rong-Rong Jin; Wei Yang; Qi Xiang; Wen-Ze Yu; Qian Lin; Fu-Rong Tian; Kai-Li Mao; Chuan-Zhu Lv; Yi-Xiáng J Wáng; Cui-Tao Lu
Journal:  PLoS One       Date:  2016-02-19       Impact factor: 3.240

8.  CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.

Authors:  Richard E Kast; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2014-09-30

9.  Neuropeptide-induced modulation of carcinogenesis in a metastatic breast cancer cell line (MDA-MB-231LUC+).

Authors:  Silvia Gutierrez; M Danilo Boada
Journal:  Cancer Cell Int       Date:  2018-12-22       Impact factor: 5.722

10.  Seeding of breast cancer cell line (MDA-MB-231LUC+) to the mandible induces overexpression of substance P and CGRP throughout the trigeminal ganglion and widespread peripheral sensory neuropathy throughout all three of its divisions.

Authors:  Silvia Gutierrez; James C Eisenach; M Danilo Boada
Journal:  Mol Pain       Date:  2021 Jan-Dec       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.